866-997-4948(US-Canada Toll Free)

Selective COX Inhibitors -Pipeline Insights, 2014

Published By :

DelveInsight

Published Date : Aug 2014

Category :

Pharmaceutical

No. of Pages : N/A


The Report will be Dispatched in 3 Working Days. 

DelveInsights,Selective COX Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Selective COX Inhibitors. This report provides information on the therapeutic development based on the Selective COX Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope 

  • The report provides a snapshot of the global therapeutic landscape of Selective COX Inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Selective COX Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Selective COX Inhibitors and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects 
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages 
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy 

  • Complete MOA intelligence and complete understanding over therapeutics development for Selective COX Inhibitors
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
  • Devise corrective measures for pipeline projects by understanding Selective COX Inhibitors pipeline depth and focus of Indication therapeutics  
  • Developing strategic initiatives to support your drug development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies  
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Content

Selective COX Inhibitors Overview
Selective COX Inhibitors Disease Associated
Selective COX Inhibitors Pipeline Therapeutics
Selective COX Inhibitors Therapeutics under Development by Companies 
Selective COX Inhibitors Late Stage Products (Filed and Phase III)
Comparative Analysis 
Selective COX Inhibitors Mid Clinical Stage Products (Phase II)
Comparative Analysis 
Selective COX Inhibitors Early Clinical Stage Products (Phase I and IND Filed)
Comparative Analysis 
Selective COX Inhibitors Discovery and Pre-Clinical Stage Products 
Comparative Analysis 
Drug Candidate Profiles
Selective COX Inhibitors Therapeutics Assessment 
Assessment by Monotherapy Products 
Assessment by Combination Products 
Assessment by Route of Administration 
Assessment by Molecule Type 
Selective COX Inhibitors Discontinued Products 
Selective COX Inhibitors Dormant Products
Companies Involved in Therapeutics Development for Selective COX Inhibitors 

Appendix 
Methodology 
Contact Us 
Disclaimer

List of Table


Number of Products under Development for Selective COX Inhibitors by Therapy Area, 2014
Number of Products under Development for Selective COX Inhibitors, 2014
Number of Products under Development by Companies 
Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
Drug Candidates Profiles
Selective COX Inhibitors Assessment by Monotherapy Products 
Selective COX Inhibitors Assessment by Combination Products 
Selective COX Inhibitors Assessment by Route of Administration 
Selective COX Inhibitors Assessment by Stage and Route of Administration 
Selective COX Inhibitors Assessment by Molecule Type 
Selective COX Inhibitors Assessment by Stage and Molecule Type 
Selective COX Inhibitors Therapeutics Discontinued Products 
Selective COX Inhibitors Therapeutics Dormant Products
Products under Development by Companies, 2014

List of Chart


Number of Products under Development for Selective COX Inhibitors by Therapy Area, 2014
Number of Products under Development for Selective COX Inhibitors, 2014
Late Clinical Stage Products (Filed and Phase III), 2014
Mid Clinical Stage Products (Phase II), 2014
Early Clinical Stage Products (Phase I and IND Filed), 2014
Discovery and Pre-Clinical Stage Products, 2014
Selective COX Inhibitors Assessment by Monotherapy Products 
Selective COX Inhibitors Assessment by Combination Products 
Selective COX Inhibitors Assessment by Route of Administration 
Selective COX Inhibitors Assessment by Stage and Route of Administration 
Selective COX Inhibitors Assessment by Molecule Type 
Selective COX Inhibitors Assessment by Stage and Molecule Type

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *